(ZBH) Zimmer Biomet Holdings - Overview
Sector: HealthcareIndustry: Medical Devices | Exchange NYSE (USA) | Currency USD | Market Cap: 17.107m | Total Return -20.3% in 12m
Stock: Orthopedic Implants, Robotics, Surgical Tools, Digital Platform
Total Rating 50
Risk 93
Buy Signal -0.68
| Risk 5d forecast | |
|---|---|
| Volatility | 24.4% |
| Relative Tail Risk | -6.71% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.71 |
| Alpha | -29.31 |
| Character TTM | |
|---|---|
| Beta | 0.690 |
| Beta Downside | 0.431 |
| Drawdowns 3y | |
|---|---|
| Max DD | 39.79% |
| CAGR/Max DD | -0.28 |
EPS (Earnings per Share)
Revenue
Description: ZBH Zimmer Biomet Holdings March 03, 2026
Zimmer Biomet Holdings Inc. (NYSE: ZBH) is a global medical-technology firm that designs, manufactures and markets a broad portfolio of orthopedic and cranio-maxillofacial products, including knee and hip implants, sports-medicine solutions, bone cement, and integrated digital-robotic platforms such as the ROSA robot and the ZBEdge data suite. Its offerings serve orthopedic surgeons, neurosurgeons, hospitals and other healthcare providers worldwide, leveraging AI-driven analytics to improve surgical outcomes.
In FY 2025 the company generated $8.2 billion in revenue, a 4 % year-over-year increase, with an operating margin of 12.5 % and adjusted EPS of $5.10. R&D spending reached $950 million, reflecting a continued focus on robotics-ROSA robot shipments rose 22 % YoY, driving an 18 % growth in the robotics segment. The orthopedic device market is being propelled by an aging U.S. population, with procedure volumes projected to expand ~3 % annually, and a favorable reimbursement environment that is stabilizing supply-chain pressures across the sector.
For deeper insight, you may want to explore ValueRay’s analytical tools.
Headlines to watch out for
- Aging global population increases demand for orthopedic products
- Hospital capital expenditure directly impacts device sales
- Regulatory approval delays hinder new product launches
- Competitive pricing pressure impacts reconstructive product margins
- Supply chain disruptions raise manufacturing costs
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 705.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 2.66 > 1.0 |
| NWC/Revenue: 30.81% < 20% (prev 28.92%; Δ 1.89% < -1%) |
| CFO/TA 0.07 > 3% & CFO 1.70b > Net Income 705.2m |
| Net Debt (6.93b) to EBITDA (2.22b): 3.12 < 3 |
| Current Ratio: 1.98 > 1.5 & < 3 |
| Outstanding Shares: last quarter (198.1m) vs 12m ago -0.90% < -2% |
| Gross Margin: 69.71% > 18% (prev 0.71%; Δ 6.90k% > 0.5%) |
| Asset Turnover: 37.03% > 50% (prev 35.94%; Δ 1.09% > 0%) |
| Interest Coverage Ratio: 3.84 > 6 (EBITDA TTM 2.22b / Interest Expense TTM 292.8m) |
Altman Z'' 3.87
| A: 0.11 (Total Current Assets 5.12b - Total Current Liabilities 2.58b) / Total Assets 23.09b |
| B: 0.50 (Retained Earnings 11.61b / Total Assets 23.09b) |
| C: 0.05 (EBIT TTM 1.12b / Avg Total Assets 22.23b) |
| D: 1.12 (Book Value of Equity 11.61b / Total Liabilities 10.39b) |
| Altman-Z'' Score: 3.87 = AA |
Beneish M -2.94
| DSRI: 1.07 (Receivables 1.70b/1.48b, Revenue 8.23b/7.68b) |
| GMI: 1.03 (GM 69.71% / 71.46%) |
| AQI: 1.00 (AQ_t 0.68 / AQ_t-1 0.69) |
| SGI: 1.07 (Revenue 8.23b / 7.68b) |
| TATA: -0.04 (NI 705.2m - CFO 1.70b) / TA 23.09b) |
| Beneish M-Score: -2.94 (Cap -4..+1) = A |
What is the price of ZBH shares?
As of March 28, 2026, the stock is trading at USD 88.57 with a total of 2,272,815 shares traded.
Over the past week, the price has changed by +0.80%, over one month by -10.03%, over three months by -1.90% and over the past year by -20.25%.
Over the past week, the price has changed by +0.80%, over one month by -10.03%, over three months by -1.90% and over the past year by -20.25%.
Is ZBH a buy, sell or hold?
Zimmer Biomet Holdings has received a consensus analysts rating of 3.45.
Therefor, it is recommend to hold ZBH.
- StrongBuy: 5
- Buy: 6
- Hold: 16
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the ZBH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 102.3 | 15.5% |
| Analysts Target Price | 102.3 | 15.5% |
ZBH Fundamental Data Overview March 26, 2026
P/E Trailing = 24.3155
P/E Forward = 10.4493
P/S = 2.0782
P/B = 1.3539
P/EG = 0.6039
Revenue TTM = 8.23b USD
EBIT TTM = 1.12b USD
EBITDA TTM = 2.22b USD
Long Term Debt = 6.93b USD (from longTermDebt, last quarter)
Short Term Debt = 587.1m USD (from shortTermDebt, last quarter)
Debt = 7.52b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.93b USD (from netDebt column, last quarter)
Enterprise Value = 24.03b USD (17.11b + Debt 7.52b - CCE 591.9m)
Interest Coverage Ratio = 3.84 (Ebit TTM 1.12b / Interest Expense TTM 292.8m)
EV/FCF = 13.00x (Enterprise Value 24.03b / FCF TTM 1.85b)
FCF Yield = 7.69% (FCF TTM 1.85b / Enterprise Value 24.03b)
FCF Margin = 22.45% (FCF TTM 1.85b / Revenue TTM 8.23b)
Net Margin = 8.57% (Net Income TTM 705.2m / Revenue TTM 8.23b)
Gross Margin = 69.71% ((Revenue TTM 8.23b - Cost of Revenue TTM 2.49b) / Revenue TTM)
Gross Margin QoQ = 64.68% (prev 72.05%)
Tobins Q-Ratio = 1.04 (Enterprise Value 24.03b / Total Assets 23.09b)
Interest Expense / Debt = 0.96% (Interest Expense 71.9m / Debt 7.52b)
Taxrate = 15.13% (125.7m / 830.8m)
NOPAT = 953.6m (EBIT 1.12b * (1 - 15.13%))
Current Ratio = 1.98 (Total Current Assets 5.12b / Total Current Liabilities 2.58b)
Debt / Equity = 0.59 (Debt 7.52b / totalStockholderEquity, last quarter 12.71b)
Debt / EBITDA = 3.12 (Net Debt 6.93b / EBITDA 2.22b)
Debt / FCF = 3.75 (Net Debt 6.93b / FCF TTM 1.85b)
Total Stockholder Equity = 12.60b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.17% (Net Income 705.2m / Total Assets 23.09b)
RoE = 5.60% (Net Income TTM 705.2m / Total Stockholder Equity 12.60b)
RoCE = 5.75% (EBIT 1.12b / Capital Employed (Equity 12.60b + L.T.Debt 6.93b))
RoIC = 4.72% (NOPAT 953.6m / Invested Capital 20.19b)
WACC = 6.09% (E(17.11b)/V(24.63b) * Re(8.41%) + D(7.52b)/V(24.63b) * Rd(0.96%) * (1-Tc(0.15)))
Discount Rate = 8.41% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.55%
[DCF] Terminal Value 86.75% ; FCFF base≈1.57b ; Y1≈1.70b ; Y5≈2.12b
[DCF] Fair Price = 274.3 (EV 60.59b - Net Debt 6.93b = Equity 53.66b / Shares 195.7m; r=6.09% [WACC]; 5y FCF grow 9.57% → 3.0% )
EPS Correlation: 63.08 | EPS CAGR: 11.48% | SUE: 0.74 | # QB: 0
Revenue Correlation: 86.41 | Revenue CAGR: 8.31% | SUE: 1.88 | # QB: 1
EPS next Quarter (2026-06-30): EPS=2.05 | Chg7d=+0.001 | Chg30d=+0.001 | Revisions Net=-14 | Analysts=24
EPS current Year (2026-12-31): EPS=8.41 | Chg7d=-0.001 | Chg30d=-0.001 | Revisions Net=-14 | Growth EPS=+2.5% | Growth Revenue=+3.8%
EPS next Year (2027-12-31): EPS=9.01 | Chg7d=+0.013 | Chg30d=+0.013 | Revisions Net=-9 | Growth EPS=+7.2% | Growth Revenue=+3.6%
[Analyst] Revisions Ratio: -0.70 (3 Up / 17 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.3% (Discount Rate 8.4% - Earnings Yield 4.1%)
[Growth] Growth Spread = -1.0% (Analyst 3.3% - Implied 4.3%)
P/E Forward = 10.4493
P/S = 2.0782
P/B = 1.3539
P/EG = 0.6039
Revenue TTM = 8.23b USD
EBIT TTM = 1.12b USD
EBITDA TTM = 2.22b USD
Long Term Debt = 6.93b USD (from longTermDebt, last quarter)
Short Term Debt = 587.1m USD (from shortTermDebt, last quarter)
Debt = 7.52b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.93b USD (from netDebt column, last quarter)
Enterprise Value = 24.03b USD (17.11b + Debt 7.52b - CCE 591.9m)
Interest Coverage Ratio = 3.84 (Ebit TTM 1.12b / Interest Expense TTM 292.8m)
EV/FCF = 13.00x (Enterprise Value 24.03b / FCF TTM 1.85b)
FCF Yield = 7.69% (FCF TTM 1.85b / Enterprise Value 24.03b)
FCF Margin = 22.45% (FCF TTM 1.85b / Revenue TTM 8.23b)
Net Margin = 8.57% (Net Income TTM 705.2m / Revenue TTM 8.23b)
Gross Margin = 69.71% ((Revenue TTM 8.23b - Cost of Revenue TTM 2.49b) / Revenue TTM)
Gross Margin QoQ = 64.68% (prev 72.05%)
Tobins Q-Ratio = 1.04 (Enterprise Value 24.03b / Total Assets 23.09b)
Interest Expense / Debt = 0.96% (Interest Expense 71.9m / Debt 7.52b)
Taxrate = 15.13% (125.7m / 830.8m)
NOPAT = 953.6m (EBIT 1.12b * (1 - 15.13%))
Current Ratio = 1.98 (Total Current Assets 5.12b / Total Current Liabilities 2.58b)
Debt / Equity = 0.59 (Debt 7.52b / totalStockholderEquity, last quarter 12.71b)
Debt / EBITDA = 3.12 (Net Debt 6.93b / EBITDA 2.22b)
Debt / FCF = 3.75 (Net Debt 6.93b / FCF TTM 1.85b)
Total Stockholder Equity = 12.60b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.17% (Net Income 705.2m / Total Assets 23.09b)
RoE = 5.60% (Net Income TTM 705.2m / Total Stockholder Equity 12.60b)
RoCE = 5.75% (EBIT 1.12b / Capital Employed (Equity 12.60b + L.T.Debt 6.93b))
RoIC = 4.72% (NOPAT 953.6m / Invested Capital 20.19b)
WACC = 6.09% (E(17.11b)/V(24.63b) * Re(8.41%) + D(7.52b)/V(24.63b) * Rd(0.96%) * (1-Tc(0.15)))
Discount Rate = 8.41% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.55%
[DCF] Terminal Value 86.75% ; FCFF base≈1.57b ; Y1≈1.70b ; Y5≈2.12b
[DCF] Fair Price = 274.3 (EV 60.59b - Net Debt 6.93b = Equity 53.66b / Shares 195.7m; r=6.09% [WACC]; 5y FCF grow 9.57% → 3.0% )
EPS Correlation: 63.08 | EPS CAGR: 11.48% | SUE: 0.74 | # QB: 0
Revenue Correlation: 86.41 | Revenue CAGR: 8.31% | SUE: 1.88 | # QB: 1
EPS next Quarter (2026-06-30): EPS=2.05 | Chg7d=+0.001 | Chg30d=+0.001 | Revisions Net=-14 | Analysts=24
EPS current Year (2026-12-31): EPS=8.41 | Chg7d=-0.001 | Chg30d=-0.001 | Revisions Net=-14 | Growth EPS=+2.5% | Growth Revenue=+3.8%
EPS next Year (2027-12-31): EPS=9.01 | Chg7d=+0.013 | Chg30d=+0.013 | Revisions Net=-9 | Growth EPS=+7.2% | Growth Revenue=+3.6%
[Analyst] Revisions Ratio: -0.70 (3 Up / 17 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.3% (Discount Rate 8.4% - Earnings Yield 4.1%)
[Growth] Growth Spread = -1.0% (Analyst 3.3% - Implied 4.3%)